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Abstract
Background: Early gastric cancer is defined as a lesion confined to the mucosa or submucosa, regardless of the
size or lymph node metastasis. Treatment methods include endoscopic mucosal resection or endoscopic submucosal
dissection, wedge resection, laparoscopically assisted gastrectomy and open gastrectomy. Lymph node metastasis is
strong related with survival and recurrence. Therefore, the likelihood of lymph node metastasis is one of the most
important factors when determining the most appropriate treatment.
Methods: We retrospectively analyzed 597 patients who underwent D2 gastrectomy for early gastric cancer. The
relationship between lymph node metastasis and clinicopathological features was analyzed. Using multivariate logistic
regression analyses, we created a nomogram to predict the lymph node metastasis probability for early gastric cancer.
Receiver operating characteristic analyses was performed to assess the predictive value of the model.
Results: In the present study, 58 (9.7 %) early gastric cancer patients were histologically shown to have lymph node
metastasis. The multivariate logistic regression analysis demonstrated that the age at diagnosis, differentiation status,
the presence of ulcers, lymphovascular invasion and depth of invasion were independent risk factors for lymph node
metastasis in early gastric cancer. Additionally, the tumor macroscopic type, size and histology type significantly
correlated with these important independent factors. We constructed a predictive nomogram with these factors for
lymph node metastasis in early gastric cancer patients, and the discrimination was good with the AUC of 0.860 (95 %
CI: 0.809–0.912).
Conclusions: We developed an effective nomogram to predict the incidence of lymph node metastasis for early
gastric cancer patients.
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Background
Gastric cancer is currently among the most common
cancer worldwide and the second most common cause
of cancer-related death [1–3]. Early gastric cancer (EGC)
is defined as a lesion confined to the mucosa or sub-
mucosa, regardless of the size or the presence of regional
lymph node metastasis [4–7]. Treatment options for
EGC include endoscopic mucosal resection (EMR) or
endoscopic submucosal dissection (ESD), wedge resection,
laparoscopically assisted gastrectomy and open gastrec-
tomy [8, 9]. Currently, although gastrectomy plus lymph
node dissection is still the gold standard of treatment for
EGCs, endoscopic surgical techniques have been widely
accepted as an alternate treatment for EGC patients with
the appropriate criteria to maintain the quality of life for a
subgroup of EGC patients [7, 10–12]. Technically, endo-
scopic surgery is used to dissect the mucosal or the sub-
mucosal layer, with regional lymph nodes left untreated.
Thus, identifying patients with a high risk of lymph node
metastasis is crucially important for the application of
endoscopic surgery.
The likelihood of lymph node metastasis is one of the
most important factors to consider when determining
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the most appropriate treatment. The absence of lymph
node metastasis is a prerequisite for EMR/ESD [12],
which preserves gastric function and maintains quality
of life by avoiding a radical gastrectomy. Endoscopic re-
section for EGC is currently the established choice of
treatment in Korea and Japan because it is both minim-
ally invasive and effective in the curative management of
EGC [13, 14]. Endoscopic resection with curative intent
is indicated only in tumors that fulfill the endoscopic re-
section criteria because these tumors rarely metastasize
to lymph nodes [15]. Recently, based on a large-scale
case series, expanded indications for endoscopic resec-
tion have been proposed because those tumors meeting
the expanded criteria had no risk of lymph node metas-
tasis [16]. Previous studies have suggested that the
definite indications of endoscopic resection include
differentiated adenocarcinoma, intramucosal cancer, a
tumor size up to 20 mm and the absence of ulceration
[17–19]. In the era of endoscopic resection, the accurate
prediction of the risk of lymph node metastasis in EGC
is crucial to select patients suitable for this procedure.
Nomograms have been developed to quantify risk fac-
tors of lymph node metastasis in several carcinomas
[20, 21]. However, there is no predictive nomogram for
the risk of lymph node metastasis in EGC, especially in
the Eastern population, which has a high incidence of gas-
tric cancer [22]. The aim of the present study was to iden-
tify risk factors for lymph node metastasis and construct a
nomogram for patients with EGC to guide treatment.
Methods
Patients
Between December 1996 and December 2012, a total
number of 597 patients who underwent surgery as an
initial treatment for EGC were studied at the Peking
University Cancer Hospital. All of the patients under-
went surgery and achieved radical (R0) resection with a
D2 lymph node dissection and were histologically
proven primary EGC in accordance with the rules of the
Japanese Gastric Cancer Association (JGCA) [23]. Pa-
tient characteristics, including age and sex, were col-
lected, and information regarding tumor size, depth of
invasion, macroscopic type, histology, and lymphovascu-
lar invasion were retrieved from medical records. The
depth of tumor invasion was classified as mucosa or
submucosa. The maximum diameter of the tumor was
recorded as the tumor size. The carcinomas were classi-
fied into three macroscopic types: protruding type (type
I); superficial type [type II, including elevated (IIa), flat
type (IIb), and depressed type (IIc)]; and excavated type
(III). Tumor differentiation was classified into two
groups: the differentiated group, which included well or
moderately differentiated adenocarcinomas, and the
undifferentiated group, which included poorly or
undifferentiated adenocarcinomas. Histologic type was
classified according to the WHO classification for gastric
cancer, including adenocarcinoma, signet-ring cell car-
cinoma, mucinous adenocarcinoma, etc. Lymph node in-
volvement was classified according to the 7th edition of
the Union for International Cancer Control (UICC) pN
category: pN0, no metastasis; pN1,1–2 metastatic lymph
nodes; pN2,3–6 metastatic lymph nodes; and pN3,≥7
metastatic lymph nodes. No patients received neoadju-
vant therapy before surgery. This study was approved by
the Institutional Review Board of the Peking University
Cancer Hospital, and informed consent was obtained
from all of the individuals.
Statistical analysis and nomogram construction
All statistical analyses and graphics were performed using
the SPSS 20.0 statistical package (SPSS Inc., Chicago, IL,
USA) and R version 2.11.1 (The R Foundation for
Statistical Computing, Vienna, Austria). The associations
between lymph node metastasis and clinicopathological
parameters were analyzed using the chi-square test (or
Fisher’s exact test when appropriate). Continuous vari-
ables were transformed into an adequate form to fit the
proportional hazards and linearity assumptions. Risk fac-
tors for lymph node metastasis were studied using a bin-
ary logistic regression modeling technique [24–26].
A nomogram was developed as a tool for identifying
patients at risk for lymph node metastasis, and it pro-
vides a graphical representation of the factors that can
be used to calculate the risk of lymph node metastasis
for an individual patient by the points associated with
each risk factor. The predictive accuracy of the model
was graphically displayed using the receiver operating
characteristic curve (ROC). The accuracy of the nomo-
gram was then quantified using the area under the curve
(AUC) for validation. An AUC of 1.0 indicates a perfect
concordance, whereas an AUC of 0.5 indicates no rela-
tionship [27]. The ROC curve is a plot of sensitivity ver-
sus 1-specificity for different threshold probabilities of
lymph node metastasis. The threshold probabilities are
arbitrary cutoff points used to classify patients as lymph
node metastasis and non-lymph node metastasis. The
sensitivity is defined as the probability of the model pre-
dicting a patient will have lymph node metastasis, given
that the patient has lymph node metastasis. The specifi-
city is defined as the probability of the model predicting
a patient will not have lymph node metastasis, given that
the patient does not have lymph node metastasis. Cali-
bration was performed for the constructed nomogram,
and the nomogram was internally validated using 200
repetitions of bootstrap sample corrections. The prob-
ability of lymph node metastasis was estimated with
95 % confidence intervals (95 % CI) based on binominal
distribution. P values of less than 0.05 were considered
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significant. Bootstrapping allows for the simulation of
the performance of the nomogram if it was applied to
future patients and provides an estimate of the average
optimism of the AUC.
Results
The correlations between lymph node metastasis and the
clinicopathological features of EGC patients
There were totally 597 patients involved in this study at
Peking University Cancer Hospital, including 416 men
and 181 women. 355 tumors were confined in the muco-
sal layer while 262 tumors invaded the submucosal layer.
The average age was 58 years old (range, 24–82 years
old) and the mean number of lymph nodes with metas-
tases was 1 (range, 0–25) while the mean number of the
total lymph node was 24 (range 9–60; IQR, P25:18,
P50:23, P75:29). Lymph node metastasis was confirmed
pathologically in 58 (9.7 %) patients. The number of pa-
tients of N0, N1, N2 and N3 stage were 539 (90.3 %), 39
(6.5 %), 10 (1.7 %), and 9 (1.5 %) respectively.
Lymph node metastasis was associated with age,
macroscopic type, size, histology, differentiation, ulcer,
lymphovascular invasion and depth of invasion (all p <
0.05). Patients younger than 50 years of age have a
higher probability of lymph node metastasis than older
patients (p = 0.024). The protruding and superficial-type
carcinomas have a lower possibility of lymph node me-
tastasis than the excavated and mixed type carcinomas
(p < 0.001). Tumors larger than 2 cm were more likely to
have lymph node metastases than smaller tumors (p =
0.004). Undifferentiated carcinomas and tumors with an
ulcer or lymphovascular/submucosal invasion were asso-
ciated with higher lymph node metastases (all p < 0.001).
In gastric adenocarcinomas, the incidence of lymph
node metastasis was lower than other pathological types
(p = 0.001). There was no significant difference in gender
or tumor location for lymph node metastasis (Table 1).
The nomogram for the prediction of metastatic lymph
nodes
We summarized the univariate and multivariate logistic
regression analyses of lymph node metastasis (Table 2).
The further multivariate logistic regression analysis
showed that age (p = 0.028, RR 0.444, 95%CI: 0.215–
0.916), differentiation (p = 0.002, RR 3.724, 95 % CI:
1.637–8.470), ulcer (p = 0.007, RR 2.710, 95 % CI: 1.310–
5.606), lymphovascular invasion (p < 0.001, RR 13.703,
95 % CI: 6.515–28.822), and depth of invasion (p =
0.006, RR 3.013, 95 % CI: 1.369–6.631) were positively
correlated with lymph node metastasis, indicating that
these characteristics were independent risk factors of
lymph node metastasis in EGC. Furthermore, we observed
that the tumor macroscopic type, size, and histology were
significantly correlated with the three most important
independent factors (differentiation, lymphovascular inva-
sion and depth of invasion; all p < 0.05; Table 3).
Thus, we chose these eight factors to develop a pre-
dictive nomogram for lymph node metastasis in EGC
patients. The nomogram corresponding to the model
including the possible factors that may affect the inci-
dence of lymph node metastasis is show in Fig. 1. For
each patient, points were assigned for each of these
clinicopathological features (age, macroscopic type,




Lymph node metastasis p
Negative (n = 539) Positive (n = 58)
Gender 0.901
Male 376 (90.4 %) 40 (9.6 %)
Female 163 (90.1 %) 18 (9.9 %)
Age (year) 0.024
<50 108 (85.0 %) 19 (15.0 %)
≥50 431 (91.7 %) 39 (8.3 %)
Tumor location 0.179
Upper 1/3 89 (94.7 %) 5 (5.3 %)
Middle 1/3 130 (92.9 %) 12 (8.5 %)
Low 1/3 320 (87.9 %) 41 (11.4 %)
Macroscopic type <0.001
I/II 374 (94.4 %) 22 (5.6 %)
III/Mixed 165 (82.1 %) 36 (17.9 %)
Size (cm)
<2.0 274 (93.8 %) 18 (6.2 %) 0.004
≥2.0 265 (86.9 %) 40 (13.1 %)
<1.5 203 (96.7 %) 7 (3.3 %) <0.001
≥1.5 336 (86.8 %) 51 (13.2 %)
Histology 0.001
Adenocarcinoma 403 (92.6 %) 32 (7.4 %)
Other typesa 136 (84.0 %) 26 (16.0 %)
Differentiation <0.001
Differentiated 245 (96.1 %) 10 (3.9 %)
Undifferentiated 294 (86.0 %) 48 (14.0 %)
Ulcer <0.001
Absent 463 (92.4 %) 38 (7.6 %)
Present 76 (79.2 %) 20 (20.8 %)
Lymphovascular invasion <0.001
Absent 510 (95.0 %) 27 (5.0 %)
Present 29 (48.3 %) 31 (51.7 %)
Depth of invasion <0.001
Mucosa 325 (97.0 %) 10 (3.0 %)
Submucosa 214 (81.7 %) 48 (18.3 %)
Other typesa: signet-ring cell carcinoma, mucinous adenocarcinoma, etc
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Table 2 Univariate and multivariate analysis of lymph node metastasis risk factors of early gastric cancer
Clinicopathological features Univariate analysis p Multivariate analysis p
RR (95 % CI) RR (95 % CI)
Gender
Male vs. Female 1.038 (0.578–1.865) 0.901
Age (years)
<50 vs. ≥50 0.514 (0.286–0.926) 0.027 0.444 (0.215–0.916) 0.028
Location
Upper 1/3 1.000 0.190
Middle 1/3 0.438 (0.168–1.143) 0.092
Lower 1/3 0.720 (0.367–1.415) 0.341
Macroscopic type
I + II vs. III/Mixed 3.165 (1.758–5.696) <0.001
Size (cm)
<2.0 vs. ≥2.0 2.298 (1.285–4.109) 0.005
<1.5 vs. ≥1.5 4.402 (1.960–9.885) <0.001
Histology
Adenocarcinoma vs. Other typesa 2.408 (1.385–4.185) 0.002
Differentiation
Differentiated vs. Undifferentiated 4.000 (1.982–8.072) <0.001 3.724 (1.637–8.470) 0.002
Ulcer
Absent vs. Present 3.206 (1.772–5.803) <0.001 2.710 (1.310–5.606) 0.007
Lymphovascular invasion
Absent vs. Present 20.192 (10.675–38.191) <0.001 13.703 (6.515–28.822) <0.001
Depth of invasion
Mucosa vs. Submucosa 7.290 (3.610–14.721) <0.001 3.013 (1.369–6.631) 0.006
Other typesa: signet-ring cell carcinoma, mucinous adenocarcinoma, etc
RR Relative risk




Differentiation p Lymphovascular invasion p Depth of invasion P
Differentiated (%) Undifferentiated (%) Absent (%) Present (%) Mucosa (%) Submucosa (%)
Macroscopic type 0.001 <0.001 <0.001
I/II 189 (47.7) 207 (52.3) 372 (93.9) 24 (6.1) 266 (67.2) 130 (32.8)
III/Mixed 66 (32.8) 135 (67.2) 165 (82.1) 36 (17.9) 69 (34.3) 132 (65.7)
Size (cm) <0.001 <0.001 <0.001
<2.0 149 (51.0) 143 (49.0) 278 (95.2) 14 (4.8) 191 (65.4) 101 (34.6)
≥2.0 106 (34.8) 199 (65.2) 259 (84.9) 46 (15.1) 144 (47.2) 161 (52.8)
Histology <0.001 0.255 0.724
Adenocarcinoma 241 (55.4) 194 (44.6) 395 (90.8) 40 (9.2) 246 (56.6) 189 (43.4)
Other typesa 14 (8.6) 148 (91.4) 142 (87.7) 20 (45.4) 89 (54.9) 73 (45.1)
Other typesa: signet-ring cell carcinoma, mucinous adenocarcinoma, etc
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size, histology, differentiation, ulcer, lymphovascular in-
vasion, and depth of invasion), and a total score was
calculated from the nomogram. The total points corre-
sponded to a predicted metastatic lymph node metasta-
sis probability. Furthermore, we developed a ROC
curve to estimate the predictive accuracy of the model,
which had an AUC of 0.860 (95 % CI: 0.809–0.912), im-
plying a good concordance (Fig. 2).
Discussion
Most surgeons consider D2 lymphadenectomy (dissec-
tion of all group I and group II lymph nodes) to be the
Fig. 1 A nomogram predicting the probability of metastatic lymph node involvement for patients with early gastric cancer. The probability of
metastatic lymph node involvement in early gastric cancer is calculated by drawing a line to the point on the axis for each of the following
variables: age, macroscopic type, size, histology, differentiation, ulcer, lymphovascular invasion and depth of invasion. The points for each variable
are summed and located on the total point line. Next, a vertical line is projected from the total point line to the predicted probability bottom
scale to obtain the individual probability of metastatic lymph node involvement
Fig. 2 A receiver operating characteristics (ROC) curve of the multivariate logistic regression model for predicting lymph node metastasis for patients
with early gastric cancer which had an AUC of 0.860 (95 % CI: 0.809–0.912), implying a good concordance
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standard and optimal surgical procedure for patients
with EGC within the past ten years [28, 29]. The lymph
node metastasis incidence of EGC is reported to be ap-
proximately 11 % to 18 %, and approximately 70 % to
80 % of patients will undergo overtreatment with D2
lymphadenectomy [29–32]. Recently, less invasive treat-
ments have been performed for EGC, including endo-
scopic mucosal resection and endoscopic submucosal
dissection [33, 34]. Because of recent advances in surgi-
cal instrumentation and techniques, laparoscopic proce-
dures have also been suggested as an alternative
minimally invasive treatment for EGC [35, 36]. For this
purpose, we retrospectively analyzed 597 EGC patients
based on clinical and routinely definitive pathological
characteristics to investigate the evidence used for mak-
ing medical decisions. Many cancer clinicians are in-
creasingly becoming attracted to simple tools such as
Nomograms to improve cancer treatment. In the present
study, we have developed a nomogram that could pre-
dict the incidence of lymph node metastasis in EGC
patients.
The lymph node metastasis incidence of all EGC pa-
tients was 9.7 % in the current study, 51.7 % in cancers
with lymphovascular invasion, 20.8 % in cancers with
an ulcer, 14.0 % in cancers with an undifferentiated
histology, 18.3 % in submucosal cancers, 13.1 % in lar-
ger sized tumors (≥2.0 cm), 17.9 % in macroscopic type
III/mixed, and 15.0 % in younger patients (<50 years
old), which are similar to or lower than previous results
[32, 38, 39]. In the multivariate analysis, the patients’
age at diagnosis, differentiation status, the presence of
an ulcer, lymphovascular invasion and depth of invasion
were independent factors for lymph node metastasis,
and the presence of lymphovascular invasion was con-
sidered the most important predictor. Previous surveys
have clarified the pathological characteristics of EGC
with or without nodal metastases. Histologic ulceration
of the tumor, larger size (≥20 mm) and submucosal
penetration were independent risk factors for regional
lymph node metastasis [39, 40]. Lymphovascular in-
volvement and mixed histological type tumors have
previously been reported as risk factors for nodal me-
tastases [41, 42]. In general, the depth of tumor inva-
sion reflects the progression of a tumor originating
from the mucosal layer and is significantly associated
with the presence of regional lymph node metastasis in
EGC [18]. Our results were consistent with the above
studies. Based on the previous studies and our results,
the tumor size, macroscopic type and histology were
considered to have significant clinical meaning among
the risk factors of lymph node metastasis in EGC.
Therefore, we chose these characteristic features in our
nomogram for predicting the incidence of lymph node
metastasis in EGC. This figure could generate estimates
of the likelihood of metastatic lymph node involvement.
Our nomogram appears to be simple and practical with
a relatively high area under the ROC curve of 0.860, thus
exhibiting a good performance related to a mean error
that never exceeded 5 %. These findings support our selec-
tion of variables for determining suitable treatment.
The gold standard in the curative treatment of gastric
cancer is a radical operation generally associated with
D2 lymphadenectomy which has a high success inci-
dence in early cases [43]. However, some complications
and mortality are associated with this procedure that are
not always necessary [44]. Certain groups of patients
with EGC have a lower possibility of lymph node metas-
tases, allowing less invasive treatment strategies to be
adopted for these situations [38]. Endoscopic resection
with curative intent is indicated only in tumors that ful-
fill the endoscopic resection criteria because these tu-
mors rarely metastasize to lymph nodes [16]. These
treatments preserve bodily functions and maintain qual-
ity of life. Our investigation has provided a good and
helpful method to address this issue. For example, an
undifferentiated submucosal gastric cancer patient with
an ulcer and lymphovascular invasion, who is younger
than 50 years of age, has more than an 80 % possibility
of lymph node metastasis without considering other fac-
tors. This patient is suitable for a radical operation with
lymphadenectomy or laparoscopic lymph node dissec-
tion following endoscopic dissection. In contrast, a pa-
tient with opposite characteristics, such as differentiated
mucosal cancer, without an ulcer or lymphovascular in-
vasion, and older than 50 years old, has almost no risk
of lymph node metastasis with respect to other patients
(less than 5 %), and should receive less invasive treat-
ments. Therefore, we believe our nomogram will assist
surgeons in selecting the appropriate treatment for pa-
tients with EGC with regard to the probability of lymph
node metastasis.
To our knowledge, this is the first study providing a
nomogram to predict the incidence of lymph node me-
tastasis for EGC. The potential limitations of this study
include the small cohort, and we should expand the
sample size to improve the nomogram. Additionally, this
is a single center retrospective study that needs further
external validation with different populations. In this
study, we did not use specific cutoff values of lymph
node metastasis for different treatments with EGC. Des-
pite these limitations, this nomogram offers an effective
tool to predict the incidence of lymph node metastasis
for EGC patients, with which we could select the appro-
priate treatments for patients.
Conclusions
In conclusion, the present study constructed a nomo-
gram to predict the probability of lymph node metastasis
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in EGC patients based on lymphovascular invasion,
depth of invasion, differentiation, age, macroscopic type,
size, and histology. This tool can assist clinicians and pa-
tients in quantifying the potential lymph node metastasis
incidence to make surgical decisions. Certain patients
are suitable for a radical operation or endoscopic dissec-
tion plus D2 lymphadenectomy, and some patients can
be selected for only endoscopic dissection (ESD, EMR).
For future studies, we should expand the sample size,
add additional centers to prove this nomogram, and de-
termine the cutoff value of the lymph node metastasis
incidence for different treatments.
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